Skip to main content
TRVI logo

TRVI · Trevi Therapeutics, Inc.

Track TRVI — free
$13.54 -0.18 (-1.31%)
Market Cap
$1.96B
Shares
142.56M
Volume · Nov 20 1.35M Avg daily vol (3M) 1.97M

Price & Indicators

 

Key stats

Close
$13.72
Thu 19 Nov
Open
$13.52
Thu 19 Nov
Average volume, 30 days
2.0M
shares a session
Short interest
16.9M
11.8% of shares · 10.1 days to cover
Day range
$13.27$14.20
Open $13.52 Close $13.72
52-week closing range
$9.99$19.50
Close $13.72 29.6% under the high
Short volume, last session
36%
Last earnings
Nov 9, 2026
Latest filing
10-Q · Nov 9
Price history
Jan 2020 to Nov 2026

Up next

Mar 16, 2027 Est · unconfirmed · in 17 wks

Latest documents

2026
Nov 11
Investor event
Trevi Therapeutics expects key readouts through 2028

Trevi Therapeutics expects refractory chronic cough data in the second half of next year, IPF Ocean 2 data in the second half of 27, and Ocean 1 data in the first half of 2028. It reported $299 million in cash and no debt.

6 source passages
Okay. Good morning, everyone, and welcome to the Trevi Therapeutics session. The readout is second half of next year. That's our Ocean 2 trial. That's scheduled to read out the second half of 27, the smaller trial, Ocean 2. And Ocean 1 is scheduled to read out the first half of 2028. Capitalized $299 million in cash, no debt, very clean balance sheet Open the document at this passage
Nov 9
Earnings call
Cash runway extends into 2030 as key trials advance

Trevi Therapeutics ended the third quarter of 2026 with approximately $299 million in cash, cash equivalents and marketable securities, supporting runway into 2030. Ocean 1 and Ocean 2 are underway; RCC results remain guided for the second half of 2027.

3 source passages
We ended the third quarter of 2026 with approximately $299 million in cash, cash equivalents, and marketable securities. Importantly, we are well-capitalized to execute on our development plans as our cash runway extends into 2030. We have initiated both Ocean 1 and Ocean 2 trials. We estimate we will have the results of the SSRE in the early part of the first quarter, and have reconfirmed our guidance for full trial results in the second half of 2027. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Phase 3 trials underway; cash runway expected into 2030

Trevi Therapeutics, Inc. began two Phase 3 trials of Haduvio in 2026 and expects $299.4 million in cash, cash equivalents and marketable securities to fund operations into 2030. Nine-month net loss was $52.4 million, and substantial additional capital is needed.

Read from the MD&A section
5 source passages
We initiated our Phase 3 OCEAN-1 trial in the second quarter of 2026 and initiated our Phase 3 OCEAN-2 trial in the third quarter of 2026. As of September 30, 2026, we had cash, cash equivalents and marketable securities of $299.4 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into 2030. During the nine months ended September 30, 2026, operating activities used $53.8 million of net cash, resulting from our net loss of $52.4 million and net changes in our operating assets and liabilities of $8.7 million, partially offset by net non-cash charges of $7.4 million. We will need substantial additional funding to support our continuing operations. Open the document at this passage
Nov 9
Current report 8-K
OCEAN-2 initiated with cash runway into 2030

Trevi Therapeutics initiated OCEAN-2 for IPF-related chronic cough in 2026 and aligned with the FDA on a non-IPF ILD Phase 2 trial. The company expects a cash runway into 2030 and reported a $21.5 million net loss for the third quarter.

Financial results
5 source passages
The Company is actively recruiting patients with IPF-related chronic cough in both Phase 3 OCEAN trials. The 12-week fixed-dose OCEAN-2 trial, was initiated in the third quarter of 2026, and topline results are expected in the second half of 2027. Positive meeting with the FDA on the non-IPF ILD-related chronic cough program held in October 2026; Phase 2 dose-ranging trial expected to initiate in the first quarter of 2027 Cash runway into 2030 funding key clinical milestones For the third quarter of 2026, the Company reported a net loss of $21.5 million, compared to a net loss of $11.8 million in the same period in 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$60.76M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$299.41M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.1%
Year over year · more shares
Price change (1Y)
+24.3%
Trailing year
Short interest
11.8%
Latest settlement · 10.1 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26

TL;DR. Trevi initiated the Phase 3 OCEAN-1 (IPF chronic cough) and Phase 2b LAKE (RCC) trials in Q2 2026, plans to initiate Phase 3 OCEAN-2 in Q3 2026, and ended Q2 with $318.9M in cash following an April financing of ~$162.3M net proceeds, extending runway into 2030; R&D spend rose to $15.2M and net loss widened to $17.8M.

Bullish
  • + Initiated Phase 3 OCEAN-1 trial in IPF-related chronic cough in Q2 2026
  • + April 2026 financing added ~$162.3M net proceeds; cash of $318.9M extends runway into 2030
  • + Recent competitive exit positions Haduvio as a potential first-in-class therapy across all three chronic cough indications
  • + JAMA publication of the Phase 2b CORAL trial and all six ATS 2026 submissions accepted, highlighting efficacy across cough frequencies
Bearish
  • − Net loss widened to $17.8M in Q2 2026 from $12.3M in Q2 2025
  • − LAKE trial SSRE in Q4 2026 could require sample-size increase of up to 50%

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg −0%
below
RSI (14) 50
neutral
MACD trend Negative
52-week position 39%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +6%
trailing
6-month return −2%
trailing
YTD return +10%
this year
Relative strength +4%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $14 › 200d $15 — 200d above 50d
Institutional flow Accumulating
+2% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.82% of shares out · ▲ +5.3% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
226 holders — near 3-yr high, broad support
Squeeze score 75
high risk · 0–100
Fundamentals
Strong
EPS growth +32%
Y/Y
Free cash flow $-42.1M
Balance sheet $18.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 59%
annualized · 1-yr
Max drawdown −39%
past year
ATR 6.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
−0% Neutral
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
39% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $14 › 200d $15 — 200d above 50d
Institutional flow Accumulating
+2% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.82% of shares out · ▲ +5.3% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
226 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $10 Now $14 · 39% Range high $20
vs 200-day avg -6% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and marketable securities $299.4M third quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TRVI
Trevi Therapeutics, Inc.
this stock
$1.96B +9.6% — — 11.8%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
226
% held
106.1%
Net QoQ
+2.2M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
184
View
Short & Settlement
Short Interest Rising
Shares short
16.9M
Days to cover
10.1d
Change
+848.8K sh
View
Short Volume
Short vol %
36%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
6.4K
Value
$94.6K
As of
Sep 22, 2026
View
Off-Exchange
Off-exchange %
52.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-42.8M
EPS diluted
$-0.32
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 11, 2026
This year
19

Trevi Therapeutics expects refractory chronic cough data in the second half of next year, IPF Ocean 2 data in the second half of 27, and Ocean 1 data in the first half of 2028. It reported $299 million in cash and no debt.

View
Proposed Sales
Value
$627.2K
Shares
39.5K
Filed
Sep 15, 2026
View
Exempt Offerings
Offering
$55.0M
Filed
Apr 18, 2022
View
Earnings & Events
Webcasts
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
Trevi Therapeutics Reports Third…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
TRVI +0.7% +6.0% -1.7% +1.2% +9.6%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +6.2% +12.3% +4.0% +6.5% +4.6%
Key facts CIK 1563880 CUSIP 89532M101 13F (30d) 230 filings 216 filers Visit website Investor relations